A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies (NCT07207707)
A Phase 1a, Open-label, Multicenter, Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB548 in Participants With Advanced Solid Malignancies With a KRAS G12D Mutation
🩺 Plain-English Summary (8th-Grade Level)
The goal of this trial is to learn if KQB548 works to treat patients with advanced solid malignancies with a KRAS G12D mutation. It will also learn about the safety of KQB548. The main questions it aims to answer are: * What is the safe dose of KQB548? * Does KQB548 decrease the size of the tumor? * What happens to KQB548 in the body?
Who can join: Review the eligibility criteria below.
Location: University of California, San Diego — La Jolla, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- University of California, San Diego — La Jolla, California
- University of California, Los Angeles — Los Angeles, California
- SCRI - Denver — Denver, Colorado
- University of Miami - Sylvester Comprehensive Cancer Center — Miami, Florida
- START Midwest — Grand Rapids, Michigan
- The Christ Hospital — Cincinnati, Ohio
- NEXT Oncology - Austin — Austin, Texas
- MD Anderson Cancer Center — Houston, Texas
- NEXT Oncology - Dallas — Irving, Texas
- NEXT Oncology - San Antonio — San Antonio, Texas
- University of Utah - Huntsman Cancer Institute — Salt Lake City, Utah
- NEXT Virginia — Fairfax, Virginia
- Fred Hutchison Cancer Center — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (858) 214-2700
Email: kumquatstudies@kumquatbio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor Malignancies
- Exploring the Feasibility of Cerebrospinal Fluid (CSF) and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and Primary Central Nervous System (CNS) Tumours: A Pilot Study — Toronto, Ontario
- Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors — Denver, Colorado
- Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS) — Tucson, Arizona
- Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors — Scottsdale, Arizona
- A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases — Detroit, Michigan
Explore by condition: All Solid Tumor Malignancies clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.